- Home
- YSG vs ABEO Comparison
YSG vs ABEO Comparison
Compare YSG & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YSG | ABEO |
|---|---|---|
| Founded | 2016 | 1974 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.3M | 282.5M |
| IPO Year | 2020 | 2005 |
Fundamental Metrics
Financial Performance| Metric | YSG | ABEO |
|---|---|---|
| Price | $2.43 | $4.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $18.88 |
| AVG Volume (30 Days) | 65.7K | ★ 1.1M |
| Earning Date | 11-16-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | $4.74 | $804.33 |
| Revenue Next Year | $11.48 | $119.68 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $2.15 | $4.00 |
| 52 Week High | $7.74 | $7.65 |
Technical Indicators
Market Signals| Indicator | YSG | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 41.59 | 33.10 |
| Support Level | $2.38 | $4.26 |
| Resistance Level | $3.49 | $5.83 |
| Average True Range (ATR) | 0.13 | 0.22 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 17.39 | 12.50 |
Price Performance
Historical ComparisonAbout YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands. Geographically, company operates in PRC, Europe and US regions.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.